English|MSA Capital Emerges as a Top Investment Firm in Asia with Unique Values( 三 )


Amadorbio’s core team consists of world-class pharmacologists that specialize in quantitative studies and biology experts and clinical management professionals from multinational drug development firm AstraZeneca. The company’s management capacity, quantitative pharmacology and biological analysis technology are industry-leading in the CRO sector in China. The company plans to expand globally through acquisitions and mergers in the future. It is worth noting that Sequoia Capital China and GL Ventures also invested in Amadorbio.
Investing in the biotechnology sector is already a very mature approach for investment firms in developed countries, Zeng said. The Chinese market is quickly emerging now with the support of state policies, investors and international talents. Zeng believes that biotechnology is “the next big thing” she has been looking for.
From Zeng’s perspective, MSA Capital does not try to invest in as many companies in industries with proven opportunities and potential as it can but rather look at industries that are not yet the promising industries in the eyes of investors.
MSA Capital’s investment strategy reflects its value system – the faith in making long-term and hard decisions that are right.
“There is too much noise in the investment business. It is very dangerous for investment firms to make decisions when they are heavily influenced by the noise,” Zeng explained. “It is like if you give the same information to two very different people, they might nonetheless make completely different investment decisions. This requires us to tell valuable information from noise and process information efficiently.”
MSA Capital now primarily invests in biotechnology, other cutting-edge technological sectors, the Internet industry and the lifestyle industry, etc. In the past six years, MSA Capital has invested in major resources in the biotechnology sector, building up a dedicated investment team that consists of top scientists. The company has invested in over 100 projects in TMT and healthcare.
Pyrotech is one of MSA Capital’s investment projects. It is a company dedicated to developing innovative small molecule drugs for infections and cancers. It is one of the first-in-class innovative pharmaceutical companies that are home-grown in China. “It could be considered as a milestone project in China’s drug development sector," Zeng said. MSA Capital thinks highly of Pyrotech because of academician Shao Feng’s leading research findings on pyroptosis. Shao’s findings have potential applications in treating several major diseases. Pyrotech’s co-founder Dr. Deng Tianjing also has an experienced team that understands commercialization in the industry. These are the reasons why MSA Capital wanted to invest in Pyrotech.
MSA Capital partook in AI drug development firm Silexon AI’s 100-million-yuan series A financing round in July 2021. Later in October, the investment firm invested in Pyrotech’s equity investment and genome sequencing and diagnostic equipment maker AXBIO’s million-dollar financing round. In November, MSA Capital moved to engage in the US$100 million financing round of Singleron Biotechnologies, a company dedicated to applying single-cell analysis technologies to clinical diagnosis and drug development. At the year’s end, MSA Capital led the million-dollar Pre-A+ financing round of INFI BRAIN TECH that focuses on digital healthcare solutions for brain diseases. There is no doubt that MSA Capital is allocating a lot of its resources to the biotechnology sector.
Working with overseas partners to accelerate international investmentsMSA Capital builds an investment portfolio on its base in China. The Chinese investment firm’s international projects are spearheaded by American businessman Ben Harburg. Harbug is a managing partner of MSA Capital.
Harbug has helped MSA Capital attract several partners outside of China and build MSA Capita’s international culture.

推荐阅读